This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beadling, C. Articles by Corless, C. L. Search for Related Content PubMed PubMed Citation Articles by Beadling, C. Articles by Corless, C. L.

KIT Gene Mutations and Copy Number in Melanoma Subtypes

Authors' Affiliations: ¹ Oregon Cancer Institute, ² Department of Pathology, and ³ Division of Hematology and Oncology, Oregon Health & Science University, and ⁴ VA Medical Center, Portland, Oregon; ⁵ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ⁶ Department of Pathology, Cleveland Clinic, Cleveland, Ohio; ⁷ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia; and ⁸ Department of Pathology, VA Medical Center, Palo Alto, California

Requests for reprints: Christopher L. Corless, Oregon Health and Science University, Department of Pathology (mailcode L471), 3181 Southwest Sam Jackson Park Road, Portland, OR 97239. Phone: 503-494-6834; Fax: 503-494-6787; E-mail: corlessc{at}ohsu.edu.

Purpose: We recently identified a KIT exon 11 mutation in an anorectal melanoma of a patient who had an excellent response to treatment with imatinib. To determine the frequency of KIT mutations across melanoma subtypes, we surveyed a large series of tumors.

Experimental Design: One hundred eighty-nine melanomas were screened for mutations in KIT exons 11, 13, and 17. KIT copy number was assessed by quantitative PCR. A subset of cases was evaluated for BRAF and NRAS mutations. Immunohistochemistry was done to assess KIT (CD117) expression.

Results: KIT mutations were detected in 23% (3 of 13) of acral melanomas, 15.6% (7 of 45) of mucosal melanomas, 7.7% (1 of 13) of conjunctival melanomas, 1.7% (1 of 58) of cutaneous melanomas, and 0% (0 of 60) of choroidal melanomas. Almost all the KIT mutations were of the type predicted to be imatinib sensitive. There was no overlap with NRAS mutations (11.1% of acral and 24.3% of mucosal tumors) or with BRAF mutations (absent in mucosal tumors). Increased KIT copy number was detected in 27.3% (3 of 11) of acral and 26.3% (10 of 38) of mucosal melanomas, but was less common among cutaneous (6.7%; 3 of 45), conjunctival (7.1%; 1 of 14), and choroidal melanomas (0 of 28). CD117 expression, present in 39% of 105 tumors representing all melanoma types, did not correlate with either KIT mutation status or KIT copy number.

Conclusions: Our findings confirm that KIT mutations are most common in acral and mucosal melanomas but do not necessarily correlate with KIT copy number or CD117 expression. Screening for KIT mutations may open up new treatment options for melanoma patients.

This article has been cited by other articles:

				D.K. Wilkins and P.D. Nathan Review: Therapeutic opportunities in noncutaneous melanoma Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 29 - 36. [Abstract] [PDF]